Sequential evaluation of serum hepcidin in anemic myeloma patients: Study of correlations with myeloma treatment, disease variables, and anemia response

Saved in:
Bibliographic Details
Published inAmerican journal of hematology Vol. 84; no. 8; pp. 524 - 526
Main Authors Katodritou, Eirini, Ganz, Tomas, Terpos, Evangelos, Verrou, Evgenia, Olbina, Gordana, Gastari, Vassiliki, Hadjiaggelidou, Christina, Varthaliti, Maria, Georgiadou, Sofia, Westerman, Mark, Zervas, Konstantinos
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.08.2009
Wiley-Liss
Subjects
Adult
Aged
Anemia - blood
Anemia - chemically induced
Anemias. Hemoglobinopathies
Antimicrobial Cationic Peptides - blood
Biological and medical sciences
Biomarkers - analysis
Biomarkers - blood
Blood Proteins - analysis
Cohort Studies
Diseases of red blood cells
Female
Hematologic and hematopoietic diseases
Hepcidins
Humans
Immunodeficiencies. Immunoglobulinopathies
Immunoglobulinopathies
Immunologic Factors - administration & dosage
Immunologic Factors - adverse effects
Immunopathology
Iron - metabolism
Male
Medical sciences
Middle Aged
Multiple Myeloma - blood
Multiple Myeloma - drug therapy
Human
Immunopathology
Hematology
Anemia
Treatment efficiency
B cell neoplasm
Malignant hemopathy
Lymphoid neoplasm
Myeloma
Immunoglobulinopathy
Sequential
Lymphoproliferative syndrome
Serum
Hepcidin
Cancer
Online AccessGet full text

Cover

More Information
Bibliography:Conflict of interest: Nothing to report.
Correction made after initial online publication. This article was published online 11 May 2009. An error in the spelling of the name was subsequently identified. This notice is included in the online and print versions to indicate that the fifth author's name should be spelled Gordana Olbina.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0361-8609
1096-8652
DOI:10.1002/ajh.21448